Literature DB >> 9803459

Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice.

J F Watchko1, M J Daood, T W Hansen.   

Abstract

P-glycoprotein (P-gp), encoded by the mdr1a gene, is an ATP-dependent plasma membrane protein that is expressed in abundance on the blood-brain barrier (BBB). P-gp limits the CNS influx and retention of a variety of lipophilic compounds. We hypothesized that brain bilirubin content after an i.v. bilirubin infusion would be increased in P-gp-deficient mdr1a null mutant transgenic mice (mdr1a(-/-)) compared with controls. Eighteen mdr1a(-/-) null mutant and 18 P-gp-sufficient wild type mice (+/+) were anesthetized and 50 mg/kg bilirubin infused through the tail vein. Brain bilirubin content (mean +/- SEM) 10 min after infusion was significantly higher in mdr1a(-/-) (18.1 +/- 2.4 nmol/g) compared with (+/+) mice (10.4 +/- 1.0 nmol/g). Brain bilirubin content declined 60 min after infusion but remained higher in mdr1a(-/-) (10.3 +/- 1.4 nmol/g) compared with (+/+) mice (5.3 +/- 0.9 nmol/g). Brain bilirubin clearance did not differ between groups (t 1/2 approximately 55 min). We conclude that P-gp-deficient mdr1a(-/-) mice have significantly higher brain bilirubin content compared with controls after an i.v. bilirubin load. These data suggest that 1) bilirubin is a substrate for P-gp and 2) the increased brain bilirubin content in mdr1a(-/-) mice is due to enhanced brain bilirubin influx. We speculate that BBB P-gp provides a protective effect against bilirubin neurotoxicity by reducing brain bilirubin influx.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9803459     DOI: 10.1203/00006450-199811000-00020

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

Review 1.  The blood-brain barrier and bilirubin encephalopathy.

Authors:  R P Wennberg
Journal:  Cell Mol Neurobiol       Date:  2000-02       Impact factor: 5.046

2.  Bilirubin, a curse and a boon.

Authors:  J D Ostrow; C Tiribelli
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 3.  Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns.

Authors:  Jon F Watchko
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

4.  HIF-1α-induced xenobiotic transporters promote Th17 responses in Crohn's disease.

Authors:  Anyan Xie; René J Robles; Samiran Mukherjee; Haohai Zhang; Linda Feldbrügge; Eva Csizmadia; Yan Wu; Keiichi Enjyoji; Alan C Moss; Leo E Otterbein; Francisco J Quintana; Simon C Robson; Maria Serena Longhi
Journal:  J Autoimmun       Date:  2018-08-08       Impact factor: 7.094

Review 5.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 6.  Developmental, Genetic, Dietary, and Xenobiotic Influences on Neonatal Hyperbilirubinemia.

Authors:  Mei-Fei Yueh; Shujuan Chen; Nghia Nguyen; Robert H Tukey
Journal:  Mol Pharmacol       Date:  2017-03-10       Impact factor: 4.436

7.  Pharmacokinetics-Based Optimization of Phototherapy in Neonates Undergoing Treatment for Hyperbilirubinemia.

Authors:  Dibyajyoti Saikia; Subodh Kumar; T Velpandian; A K Deorari; N R Biswas; Y K Gupta
Journal:  Maedica (Bucur)       Date:  2021-12

8.  Moxidectin toxicity in senescence-accelerated prone and resistant mice.

Authors:  Vanessa K Lee; Asheesh K Tiwary; Prachi Sharma-Reddy; Karen A Lieber; Douglas K Taylor; Deborah M Mook
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

9.  ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.

Authors:  M Daood; C Tsai; M Ahdab-Barmada; J F Watchko
Journal:  Neuropediatrics       Date:  2009-01-22       Impact factor: 1.947

10.  Exposure to lipopolysaccharide and/or unconjugated bilirubin impair the integrity and function of brain microvascular endothelial cells.

Authors:  Filipa L Cardoso; Agnes Kittel; Szilvia Veszelka; Inês Palmela; Andrea Tóth; Dora Brites; Mária A Deli; Maria A Brito
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.